New drug cocktail aims to tackle tough pancreatic cancer

NCT ID NCT06313970

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing an experimental immunotherapy drug called QL1706 combined with standard chemotherapy (nab-paclitaxel and gemcitabine), with or without the targeted drug bevacizumab, as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 58 participants in China to see if the combination can shrink tumors and control the disease. Researchers will also monitor safety and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (an experimental immunotherapy drug) combined with chemotherapy drugs nab-paclitaxel and gemcitabine, with or without bevacizumab
What this could lead to: If successful, this could point toward a more effective first-line treatment option for advanced pancreatic cancer, potentially shrinking tumors and extending life.
What could go wrong: This is an early Phase 2 exploratory study with only 58 participants, so results may not apply broadly. The drug combination may cause significant side effects, and there is no guarantee it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.